Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) generates a steady flow of news as a clinical-stage oncology company advancing RNA-targeted therapeutics for cancer. This news page aggregates press releases and third-party coverage related to TransCode’s development programs, corporate actions, and scientific collaborations, giving readers a centralized view of how the company’s RNA oncology strategy is progressing.
Much of the company’s news focuses on its lead candidate, TTX-MC138, an RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which TransCode identifies as a key factor in metastatic cancer. Updates include milestones from its Phase 0 and Phase 1a clinical trials in metastatic solid tumors, reports on safety and pharmacodynamic data, and announcements about advancing TTX-MC138 into Phase 2a studies across selected metastatic indications and minimal residual disease settings.
Readers can also follow news about preclinical research using the TTX platform, such as studies in glioblastoma models demonstrating delivery of TTX-MC138 to brain tumors, target engagement, and extended survival in murine models. These items highlight how TransCode’s nanoparticle platform is being evaluated for systemic delivery of RNA therapeutics to challenging tumor sites.
Beyond clinical and preclinical data, TransCode’s news includes corporate and strategic developments, such as the acquisition of Polynoma and the addition of seviprotimut-L, a polyvalent shed antigen vaccine for stage IIB and IIC melanoma, to its pipeline. Filings and releases also cover financing transactions with affiliates of CK Life Sciences, reverse stock split decisions related to Nasdaq listing requirements, and governance updates including board and executive appointments.
For investors, researchers, and clinicians, following RNAZ news offers insight into TransCode’s progress in metastatic disease, its expanding immuno-oncology and RNA pipeline, and the regulatory and capital markets events that shape its development path. Bookmark this page to review new trial readouts, platform data, and transaction announcements as they are released.
TransCode Therapeutics (NASDAQ: RNAZ) announced positive preliminary data from its Phase 0 clinical trial for TTX-MC138, their lead RNA-based therapeutic candidate. The trial showed significant inhibition of the molecular target miRNA-10b, with a 66% reduction in the patient's blood 24 hours post-administration. This inhibition is linked to complete regressions of metastatic disease in animal models. The study also revealed effective delivery of TTX-MC138 to metastatic tumors and no adverse events were observed, indicating the treatment's safety at a microdose. These findings support further clinical development, with a Phase 1 study planned to explore TTX-MC138's potential for treating multiple metastatic cancers.
TransCode Therapeutics issued an open letter to shareholders regarding a proposed reverse split of their stock due to not meeting the Minimum Bid Requirement. The company faces potential delisting from Nasdaq but intends to appeal the decision. They believe a reverse split is the best chance to maintain Nasdaq listing. The Board and Management express their reluctance but emphasize the importance of shareholder support.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.